Literature DB >> 6674249

Why may epsilon-aminocaproic acid (EACA) induce myopathy in man? Report of a case and literature review.

G Galassi, M Gibertoni, L Corradini, A Colombo.   

Abstract

A case of necrotizing myopathy due to a short epsilon-aminocaproic acid (EACA) treatment in a 72 year-old patient with subarachnoid haemorrhage (SAH) is described. Pathogenetic hypotheses are discussed.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6674249     DOI： 10.1007/bf02125632

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN： 0392-0461


  9 in total

1.  Letter: Epsilon-aminocaproic acid and subarachnoid haemorrhage.?211.

Authors:  M D Shaw; J D Miller
Journal:  Lancet       Date:  1974-10-05       Impact factor: 79.321

2.  Animal model for EACA-induced myopathy.

Authors:  S T Iannaccone; R C Griggs
Journal:  Muscle Nerve       Date:  1981 Mar-Apr       Impact factor: 3.217

3.  Extensive muscle necrosis after long-term treatment with aminocaproic acid (EACA) in a case of hereditary periodic edema.

Authors:  K Korsan-Bengtsen; L Ysander; G Blohmé; E Tibblin
Journal:  Acta Med Scand       Date:  1969-04

4.  Intracranial aneurysms and subarachnoid hemorrhage. A cooperative study. Antifibrinolytic therapy in recent onset subarachnoid hemorrhage.

Authors:  D W Nibbelink; J C Torner; W G Henderson
Journal:  Stroke       Date:  1975 Nov-Dec       Impact factor: 7.914

5.  Epsilon-aminocaproic acid myopathy. Report of a case and literature review.

Authors:  J A Vanneste; G K van Wijngaarden
Journal:  Eur Neurol       Date:  1982       Impact factor: 1.710

6.  Myopathy associated with epsilon-aminocaproic acid (EACA) therapy. Report of two cases.

Authors:  A R MacKay; H Sang U; P R Weinstein
Journal:  J Neurosurg       Date:  1978-10       Impact factor: 5.115

7.  Myopathy induced by epsilon-aminocaproic acid. Case report.

Authors:  J A Brown; R L Wollmann; S Mullan
Journal:  J Neurosurg       Date:  1982-07       Impact factor: 5.115

8.  Rhabdomyolysis during treatment with epsilon-aminocaproic acid.

Authors:  C W Britt; R R Light; B H Peters; S S Schochet
Journal:  Arch Neurol       Date:  1980-03

9.  Myopathy due to epsilon amino-caproic acid.

Authors:  C Kennard; M Swash; R A Henson
Journal:  Muscle Nerve       Date:  1980 May-Jun       Impact factor: 3.217
  9 in total
  3 in total

Review 1.  Clinical features, pathogenesis and management of drug-induced rhabdomyolysis.

Authors:  C Köppel
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Mar-Apr

Review 2.  Antifibrinolytic agents in subarachnoid haemorrhage.

Authors:  K W Lindsay
Journal:  J Neurol       Date:  1987-01       Impact factor: 4.849

Review 3.  Antifibrinolytic therapy to prevent early rebleeding after subarachnoid hemorrhage.

Authors:  Mark Chwajol; Robert M Starke; Grace H Kim; Stephan A Mayer; E Sander Connolly
Journal:  Neurocrit Care       Date:  2008       Impact factor: 3.210
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.